Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial David A. ReardonPatrick Y. WenMichael A. Vogelbaum Original Article 30 October 2011 Pages: 849 - 860
Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer Yoshinori MakinoNoboru YamamotoHiroshi Yamamoto Original Article 01 November 2011 Pages: 861 - 869
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes M. CamponeN. IsambertP. Fumoleau Original Article 02 November 2011 Pages: 871 - 879
The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia Emma K. HanssonLena E. Friberg Original Article 05 November 2011 Pages: 881 - 890
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) H. MurakamiT. TamuraN. Yamamoto Original Article 10 November 2011 Pages: 891 - 899
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity Zhi-Qiang NingZhi-Bin LiXian-Ping Lu Original Article 12 November 2011 Pages: 901 - 909
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model Yanping LuoFang JiangGerard B. Fox Original Article 12 November 2011 Pages: 911 - 921
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients Katsuya NakaiHiroyuki MitomiFujio Kasumi Original Article 15 November 2011 Pages: 923 - 930
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation Roberto CĂ©sar P. Lima-JĂşniorAline A. FigueiredoRonaldo A. Ribeiro Original Article 20 November 2011 Pages: 931 - 942
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates Jodi A. MuscalYongkai SunStacey L. Berg Original Article 23 November 2011 Pages: 943 - 947
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer Taroh SatohYasushi OmuroAtsushi Ohtsu Original Article 25 November 2011 Pages: 949 - 955
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients Chigusa MorizaneTakuji OkusakaTomohiro Yamaguchi Original Article 26 November 2011 Pages: 957 - 964
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells Vidya MamidipudiTao ShiVictoria Sung Original Article 26 November 2011 Pages: 965 - 976
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib C. CauchiN. SomaiahM. von Mehren Original Article Open access 27 November 2011 Pages: 977 - 982
Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation Andrea Elio SprioFederica Di ScipioGiovanni Nicolao Berta Original Article 04 December 2011 Pages: 983 - 989
The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers Carlo L. BelloRobert R. LaBadieM. Noella Ndongo Original Article 07 December 2011 Pages: 991 - 997
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients Naoto TakahashiMasatomo MiuraKenichi Sawada Original Article 07 December 2011 Pages: 999 - 1004
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer M. WadaM. YamamotoN. Masuda Original Article 08 December 2011 Pages: 1005 - 1011
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors Sukhmani K. PaddaYelena KrupitskayaHeather A. Wakelee Original Article Open access 11 December 2011 Pages: 1013 - 1020
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study Steven G. DuBoisSuzanne ShustermanSusan M. Blaney Original Article 18 December 2011 Pages: 1021 - 1027
CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice Ke-Ling PeiYi YuanShu-Xiang Cui Original Article 21 December 2011 Pages: 1029 - 1038
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423 Robert T. DorrLee WisnerWilliam A. Remers Original Article 21 December 2011 Pages: 1039 - 1049
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers Peter StopferKristell MarzinThomas Ebner Original Article 27 December 2011 Pages: 1051 - 1061
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose Amrita V. KamathDan LuLisa A. Damico-Beyer Original Article 28 December 2011 Pages: 1063 - 1069
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma Amrita V. KamathDan LuLisa A. Damico-Beyer Original Article 28 December 2011 Pages: 1071 - 1078
Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo Lin FangLi ShanquZhang Huizhong Original Article 29 December 2011 Pages: 1079 - 1087
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors Gopa IyerMichael J. MorrisDavid B. Solit Clinical Trial Report 29 November 2011 Pages: 1089 - 1097
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors Yoshitaka SekiNoboru YamamotoTomohide Tamura Clinical Trial Report Open access 06 December 2011 Pages: 1099 - 1105
Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity Shousong CaoFarukh A. DurraniY. Eugene Yu Short Communication 12 January 2012 Pages: 1107 - 1111
Going past the data for temozolomide J. Lee VillanoNathalie LetarteLinda R. Bressler Commentary 07 December 2011 Pages: 1113 - 1115